The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Lannett Co (LCI - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of LCI and the rest of the Medical group's stocks.
Lannett Co is one of 889 companies in the Medical group. The Medical group currently sits at #2 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. LCI is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for LCI's full-year earnings has moved 25.50% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, LCI has gained about 141.33% so far this year. At the same time, Medical stocks have lost an average of 0.28%. This means that Lannett Co is outperforming the sector as a whole this year.
Looking more specifically, LCI belongs to the Medical - Drugs industry, which includes 178 individual stocks and currently sits at #66 in the Zacks Industry Rank. On average, this group has gained an average of 0.56% so far this year, meaning that LCI is performing better in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to LCI as it looks to continue its solid performance.